{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:48:25Z","timestamp":1792759705935,"version":"4.5.0"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.intimp.2022.109183","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T02:24:59Z","timestamp":1661135099000},"page":"109183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection"],"prefix":"10.1016","volume":"112","author":[{"given":"Maedeh","family":"Vahabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tooba","family":"Ghazanfari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Sepehrnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.109183_b0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fimmu.2018.00187","article-title":"The possible effect of B-cell epitopes of Epstein-Barr virus early antigen, membrane antigen, latent membrane protein-1, and -2A on systemic lupus erythematosus","volume":"9","author":"Tu","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109183_b0010","doi-asserted-by":"crossref","unstructured":"M. EJ, et al., Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis, Nat. Med. 11(3) (2005) 335\u2013339.","DOI":"10.1038\/nm1202"},{"key":"10.1016\/j.intimp.2022.109183_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109122","article-title":"Current mechanistic insights into the role of infection in systemic lupus erythematosus","volume":"117","author":"Pan","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.intimp.2022.109183_b0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11892-019-1256-9","article-title":"Human Endogenous Retroviruses and Type 1 Diabetes","volume":"19","author":"Levet","year":"2019","journal-title":"Curr. Diab. Rep."},{"issue":"11","key":"10.1016\/j.intimp.2022.109183_b0025","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11892-018-1077-2","article-title":"Enteroviral Infections as a Trigger for Type 1 Diabetes","volume":"18","author":"Rodriguez-Calvo","year":"2018","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.intimp.2022.109183_b0030","doi-asserted-by":"crossref","unstructured":"CY, P., et al., Association of cytomegalovirus infection with autoimmune type 1 diabetes, Lancet 332(8601) (1988) 1-4.","DOI":"10.1016\/S0140-6736(88)92941-8"},{"key":"10.1016\/j.intimp.2022.109183_b0035","unstructured":"AM, E. and M. SD, The role of infections in autoimmune disease, Clin. Exp. Immunol. 155(1) (2009) 1\u201315."},{"issue":"1","key":"10.1016\/j.intimp.2022.109183_b0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cei.13239","article-title":"Pathogen infection and autoimmune disease","volume":"195","author":"Christen","year":"2019","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109183_b0045","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.2337\/db14-1020","article-title":"Viral infection of engrafted human islets leads to diabetes","volume":"64","author":"Gallagher","year":"2015","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.intimp.2022.109183_b0050","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4049\/jimmunol.167.6.3513","article-title":"T cell activation by coxsackievirus B4 antigens in type 1 diabetes mellitus: evidence for selective TCR Vbeta usage without superantigenic activity","volume":"167","author":"Varela-Calvino","year":"2001","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109183_b0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0092-8674(00)80338-4","article-title":"A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes","volume":"90","author":"Conrad","year":"1997","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2022.109183_b0060","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2249.2011.04555.x","article-title":"Immunology in the clinic review series; focus on type 1 diabetes and viruses: the enterovirus link to type 1 diabetes: critical review of human studies","volume":"168","author":"Stene","year":"2012","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109183_b0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.23736\/S0026-4806.20.07158-X","article-title":"Rheumatologic manifestations of Hepatitis C Virus","volume":"112","author":"Treppo","year":"2021","journal-title":"Minerva Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109183_b0070","first-page":"43","article-title":"Autoimmunity and HCV Infection in Porphyria Cutanea Tarda: A Controlled Study","volume":"48","author":"St\u00f6lzel","year":"2002","journal-title":"Cell. Mol. Biol."},{"key":"10.1016\/j.intimp.2022.109183_b0075","doi-asserted-by":"crossref","unstructured":"J, C., Z. H, and C. P, Correlation between systemic lupus erythematosus and cytomegalovirus infection detected by different methods, Clin. Rheumatol. 34(4) (2015) 691\u2013698.","DOI":"10.1007\/s10067-015-2868-3"},{"key":"10.1016\/j.intimp.2022.109183_b0080","first-page":"71","article-title":"Dengue fever triggering systemic lupus erythematosus and lupus nephritis: a case report","volume":"6","author":"Talib","year":"2013","journal-title":"Int. Med. Case Rep. J."},{"key":"10.1016\/j.intimp.2022.109183_b0085","doi-asserted-by":"crossref","unstructured":"S, A., et al., Parvovirus B19 infection and systemic lupus erythematosus: activation of an aberrant pathway? Eur. J. Int. Med. 19(5) (2008) 314\u2013318.","DOI":"10.1016\/j.ejim.2007.09.013"},{"issue":"3","key":"10.1016\/j.intimp.2022.109183_b0090","doi-asserted-by":"crossref","first-page":"e0193171","DOI":"10.1371\/journal.pone.0193171","article-title":"Anti-Epstein-Barr virus antibodies in Beijing during 2013\u20132017: What we have found in the different patients","volume":"13","author":"Cui","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.109183_b0095","doi-asserted-by":"crossref","unstructured":"D, C., et al., Association of clinical and serological parameters of systemic lupus erythematosus patients with Epstein-Barr virus antibody profile, J. Med. Virol. 90(3) (2018) 559\u2013563.","DOI":"10.1002\/jmv.24904"},{"key":"10.1016\/j.intimp.2022.109183_b0100","doi-asserted-by":"crossref","unstructured":"M.R.d. Costa, et al., Prevalence and genetic diversity of torque teno virus in patients with systemic lupus erythematosus in a reference service in Mato Grosso do Sul, Rev. Bras. Reumatol. 25(1) (2012) 49\u201354.","DOI":"10.1590\/S0482-50042012000100006"},{"issue":"24","key":"10.1016\/j.intimp.2022.109183_b0105","doi-asserted-by":"crossref","first-page":"e00980","DOI":"10.1128\/JVI.00980-19","article-title":"Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism","volume":"93","author":"Serafini","year":"2019","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109183_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9112191","article-title":"Epstein Barr Virus Exploits Genetic Susceptibility to Increase Multiple Sclerosis Risk","volume":"9","author":"L\u00e4derach","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.intimp.2022.109183_b0115","doi-asserted-by":"crossref","unstructured":"G, W., TuckerR, and A. Paskauskas, The MSMV hypothesis: Measles virus and multiple sclerosis, etiology and treatment, Med. Hypotheses 71(5) (2008) 682\u2013689.","DOI":"10.1016\/j.mehy.2008.06.029"},{"key":"10.1016\/j.intimp.2022.109183_b0120","doi-asserted-by":"crossref","unstructured":"C. Otto, J. Hofmann, K. Ruprecht, Antibody producing B lineage cells invade the central nervous system predominantly at the time of and triggered by acute Epstein-Barr virus infection: A hypothesis on the origin of intrathecal immunoglobulin synthesis in multiple sclerosis, Med. Hypotheses 91 (2016) 109\u2013113.","DOI":"10.1016\/j.mehy.2016.04.025"},{"key":"10.1016\/j.intimp.2022.109183_b0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clineuro.2013.12.020","article-title":"The participation of varicella zoster virus in relapses of multiple sclerosis","volume":"119","author":"Sotelo","year":"2014","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"5","key":"10.1016\/j.intimp.2022.109183_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102524","article-title":"Could Sars-coronavirus-2 trigger autoimmune and\/or autoinflammatory mechanisms in genetically predisposed subjects?","volume":"19","author":"Caso","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2022.109183_b0135","doi-asserted-by":"crossref","unstructured":"S. Najafi, E. Rajaei, R. Moallemian, The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach, 39(11) (2020) 3223\u20133235.","DOI":"10.1007\/s10067-020-05376-x"},{"issue":"2","key":"10.1016\/j.intimp.2022.109183_b0140","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/BOR.0000000000000776","article-title":"COVID-19 and autoimmune diseases","volume":"33","author":"Liu","year":"2021","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.intimp.2022.109183_b0145","doi-asserted-by":"crossref","unstructured":"R. Talotta, E. Robertson, Autoimmunity as the comet tail of COVID-19 pandemic, 8(17) (2020) 3621\u20133644.","DOI":"10.12998\/wjcc.v8.i17.3621"},{"key":"10.1016\/j.intimp.2022.109183_b0150","doi-asserted-by":"crossref","unstructured":"S, L., et al., Human Endogenous Retroviruses and Type 1 Diabetes, Curr. Diab. Rep, 19(12) (2019) p. 141.","DOI":"10.1007\/s11892-019-1256-9"},{"key":"10.1016\/j.intimp.2022.109183_b0155","doi-asserted-by":"crossref","unstructured":"Rodriguez-Calvo1, T., Enteroviral Infections as a Trigger for Type 1 Diabetes, Curr. Diab. Rep. 18(11) (2018) p. 106.","DOI":"10.1007\/s11892-018-1077-2"},{"key":"10.1016\/j.intimp.2022.109183_b0160","doi-asserted-by":"crossref","unstructured":"J, C., et al., Anti\u2010Epstein\u2013Barr virus antibodies in Beijing during 2013\u20132017: What we have found in the different patients, PLoS ONE 13 (2018) p. e0193171.","DOI":"10.1371\/journal.pone.0193171"},{"key":"10.1016\/j.intimp.2022.109183_b0165","doi-asserted-by":"crossref","unstructured":"F. L\u00e4derach, C.M. 1, Epstein Barr Virus Exploits Genetic Susceptibility to Increase Multiple Sclerosis Risk, Microorganisms. Microorganisms 9(11): p. 2191.","DOI":"10.3390\/microorganisms9112191"},{"issue":"1","key":"10.1016\/j.intimp.2022.109183_b0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12863-022-01040-2","article-title":"SARS-CoV-2 and human retroelements: a case for molecular mimicry?","volume":"23","author":"Koch","year":"2022","journal-title":"BMC Genom Data"},{"key":"10.1016\/j.intimp.2022.109183_b0175","doi-asserted-by":"crossref","unstructured":"G, L. and F. A, Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons, Autoimmun. Rev. 19(7) (2020) p. 102556.","DOI":"10.1016\/j.autrev.2020.102556"},{"key":"10.1016\/j.intimp.2022.109183_b0180","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.plipres.2019.01.004","article-title":"Hsp70 interactions with membrane lipids regulate cellular functions in health and disease","volume":"74","author":"Balogi","year":"2019","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.intimp.2022.109183_b0185","doi-asserted-by":"crossref","unstructured":"G, L., Epitopes for a 2019-nCoV vaccine, Cell Mol. Immunol. 17(5) (2020) 539\u2013540.","DOI":"10.1038\/s41423-020-0377-z"},{"issue":"1","key":"10.1016\/j.intimp.2022.109183_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12863-022-01040-2","article-title":"SARS-CoV-2 and human retroelements: a case for molecular mimicry?","volume":"23","author":"Koch","year":"2022","journal-title":"BMC Genomic Data"},{"key":"10.1016\/j.intimp.2022.109183_b0195","doi-asserted-by":"crossref","unstructured":"F, C., Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena? Cell Stress Chaperones 25(3) (2020) 381\u2013382.","DOI":"10.1007\/s12192-020-01112-1"},{"key":"10.1016\/j.intimp.2022.109183_b0200","doi-asserted-by":"crossref","unstructured":"Z, B., et al., Hsp70 interactions with membrane lipids regulate cellular functions in health and disease, Prog. Lipid Res. 74 (2019) 18\u201330.","DOI":"10.1016\/j.plipres.2019.01.004"},{"key":"10.1016\/j.intimp.2022.109183_b0205","doi-asserted-by":"crossref","unstructured":"C, C.B., et al., Hsp60 Post-translational Modifications: Functional and Pathological Consequences, Front. Mol. Biosci. 7 (2020) p. 95.","DOI":"10.3389\/fmolb.2020.00095"},{"issue":"2","key":"10.1016\/j.intimp.2022.109183_b0210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1568-9972(03)00088-0","article-title":"Autoimmunity to heat shock proteins in atherosclerosis","volume":"3","author":"Mandal","year":"2004","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2022.109183_b0215","doi-asserted-by":"crossref","unstructured":"F, C., et al., Chlamydia trachomatis infection and anti-Hsp60 immunity: the two sides of the coin, PLoS Pathog. 5(8) (2009) p. e1000552.","DOI":"10.1371\/journal.ppat.1000552"},{"key":"10.1016\/j.intimp.2022.109183_b0220","doi-asserted-by":"crossref","unstructured":"A.M. Gammazza, et al., Human molecular chaperones share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible role of molecular mimicry in COVID-19, 25(2) (2020) 737\u2013741.","DOI":"10.1007\/s12192-020-01148-3"},{"key":"10.1016\/j.intimp.2022.109183_b0225","doi-asserted-by":"crossref","unstructured":"Z. Xu, et al., Pathological findings of COVID-19 associated with acute respiratory distress syndrome, 8(4) (2020) 420\u2013422.","DOI":"10.1016\/S2213-2600(20)30076-X"},{"issue":"52","key":"10.1016\/j.intimp.2022.109183_b0230","doi-asserted-by":"crossref","first-page":"22373","DOI":"10.1073\/pnas.1012051108","article-title":"Evolving concepts of specificity in immune reactions","volume":"107","author":"Eisen","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.intimp.2022.109183_b0235","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-immunol-032414-112240","article-title":"Innate immune pattern recognition: a cell biological perspective","volume":"33","author":"Brubaker","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2022.109183_b0240","doi-asserted-by":"crossref","unstructured":"F, C., et al., The cytokine storm in COVID-19: An overview of the involvement of the chemokine\/chemokine-receptor system, Cytokine Growth Factor Rev. 53 (2020) 25\u201332.","DOI":"10.1016\/j.cytogfr.2020.05.003"},{"key":"10.1016\/j.intimp.2022.109183_b0245","doi-asserted-by":"crossref","unstructured":"JB, M. and J. CH, Cytokine release syndrome in severe COVID-19, Science 368(6490) (2020) 473\u2013474.","DOI":"10.1126\/science.abb8925"},{"issue":"7164","key":"10.1016\/j.intimp.2022.109183_b0250","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature06246","article-title":"Recognition of microorganisms and activation of the immune response","volume":"449","author":"Medzhitov","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.109183_b0255","doi-asserted-by":"crossref","unstructured":"HN, E. and C. AK, Evolving concepts of specificity in immune reactions, Proc. Natl. Acad. Sci. U S A 107(52) (2010) 22373\u201322380.","DOI":"10.1073\/pnas.1012051108"},{"key":"10.1016\/j.intimp.2022.109183_b0260","doi-asserted-by":"crossref","unstructured":"SW, B., et al., Innate immune pattern recognition: a cell biological perspective, Annu. Rev. Immunol. 33 (2015) 257\u2013290.","DOI":"10.1146\/annurev-immunol-032414-112240"},{"issue":"5","key":"10.1016\/j.intimp.2022.109183_b0265","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1002\/jmv.26826","article-title":"Role of Toll-like receptors in the pathogenesis of COVID-19","volume":"93","author":"Khanmohammadi","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.intimp.2022.109183_b0270","doi-asserted-by":"crossref","unstructured":"P, C., R. G, and C. A, Induction of pro\u2010inflammatory cytokines (IL\u20101 and IL\u20106) and lung inflammation by coronavirus\u201019 (COVI\u201019 or SARS\u2010CoV\u20102): anti\u2010inflammatory strategies, J. Biol. Regul. Homeost. Agents 34(2) (2020) 327\u2013331.","DOI":"10.23812\/CONTI-E"},{"key":"10.1016\/j.intimp.2022.109183_b0275","doi-asserted-by":"crossref","unstructured":"W. CE, et al., Network analysis of associations between serum interferon-\u03b1 activity, autoantibodies, and clinical features in systemic lupus erythematosus, Arthritis Rheum. 63(4) (2011) 1044\u20131053.","DOI":"10.1002\/art.30187"},{"key":"10.1016\/j.intimp.2022.109183_b0280","doi-asserted-by":"crossref","unstructured":"L, R., E. ML, The interferon signature in autoimmune diseases, Curr. Opin. Rheumatol. 25(2) (2013) 248\u2013253.","DOI":"10.1097\/BOR.0b013e32835c7e32"},{"issue":"2","key":"10.1016\/j.intimp.2022.109183_b0285","doi-asserted-by":"crossref","first-page":"327","DOI":"10.23812\/CONTI-E","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.intimp.2022.109183_b0290","doi-asserted-by":"crossref","unstructured":"C. IY, I. T, Response of host inflammasomes to viral infection, Trends Microbiol. 23(1) (2015) 55\u201363.","DOI":"10.1016\/j.tim.2014.09.007"},{"key":"10.1016\/j.intimp.2022.109183_b0295","doi-asserted-by":"crossref","first-page":"7527953","DOI":"10.1155\/2020\/7527953","article-title":"Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment","volume":"2020","author":"Cicco","year":"2020","journal-title":"Mediators Inflamm."},{"issue":"1","key":"10.1016\/j.intimp.2022.109183_b0300","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12985-020-01415-w","article-title":"Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents","volume":"17","author":"Khadke","year":"2020","journal-title":"Virol. J."},{"key":"10.1016\/j.intimp.2022.109183_b0305","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/194864","article-title":"Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives","volume":"2015","author":"Lopalco","year":"2015","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.intimp.2022.109183_b0310","doi-asserted-by":"crossref","unstructured":"P, C., et al., Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies, J. Biol. Regul. Homeost. Agents 34(2) (2020) 327\u2013331.","DOI":"10.23812\/CONTI-E"},{"issue":"21","key":"10.1016\/j.intimp.2022.109183_b0315","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1111\/bph.15229","article-title":"The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing","volume":"177","author":"Bertocchi","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109183_b0320","doi-asserted-by":"crossref","unstructured":"L, B., et al., The inflammasomes and autoinflammatory syndromes, Annu. Rev. Pathol. 10 (2015) 395\u2013424.","DOI":"10.1146\/annurev-pathol-012414-040431"},{"key":"10.1016\/j.intimp.2022.109183_b0325","doi-asserted-by":"crossref","unstructured":"G, L., et al., Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives, Mediators Inflamm. 2015(194864) (2015).","DOI":"10.1155\/2015\/194864"},{"issue":"8829674","key":"10.1016\/j.intimp.2022.109183_b0330","article-title":"COVID-19 and Neutrophils: The Relationship between Hyperinflammation and Neutrophil Extracellular Traps","volume":"2020","author":"Borges","year":"2020","journal-title":"Mediators Inflamm."},{"issue":"12","key":"10.1016\/j.intimp.2022.109183_b0335","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201012","article-title":"Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19","volume":"217","author":"Radermecker","year":"2020","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.intimp.2022.109183_b0340","first-page":"e138999","article-title":"Neutrophil extracellular traps in COVID-19","volume":"5","author":"Zuo","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.intimp.2022.109183_b0345","first-page":"1","article-title":"Neutrophil Extracellular Trap Formation Potential Correlates with Lung Disease Severity in COVID-19 Patients","author":"Kinnare","year":"2021","journal-title":"Inflammation"},{"issue":"12","key":"10.1016\/j.intimp.2022.109183_b0350","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201129","article-title":"SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology","volume":"217","author":"Veras","year":"2020","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.intimp.2022.109183_b0355","doi-asserted-by":"crossref","first-page":"e20201012","DOI":"10.1084\/jem.20201012","article-title":"Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19","volume":"217","author":"Radermecker","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2022.109183_b0360","unstructured":"F.P. Veras, et al., SARS-CoV-2\u2013triggered neutrophil extracellular traps mediate COVID-19 pathology, 217(12) (2020)."},{"issue":"11","key":"10.1016\/j.intimp.2022.109183_b0365","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2017.09.012","article-title":"Neutrophil extracellular traps (NETs) in autoimmune diseases: A comprehensive review","volume":"16","author":"Lee","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2022.109183_b0370","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/cells9040915","article-title":"Neutrophil Extracellular Traps (NETs) Take the Central Stage in Driving Autoimmune Responses","volume":"9","author":"Fousert","year":"2020","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.intimp.2022.109183_b0375","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome","volume":"136","author":"Middleton","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2022.109183_b0380","doi-asserted-by":"crossref","unstructured":"Nasir A, C.-A.G., A phylogenomic data-driven exploration of viral origins and evolution, Sci. Adv. 1(8) (2015) p. e1500527.","DOI":"10.1126\/sciadv.1500527"},{"key":"10.1016\/j.intimp.2022.109183_b0385","doi-asserted-by":"crossref","unstructured":"MG, N., S. A, and R. N, SARS-CoV-2-A Tough Opponent for the Immune System, Arch Med. Res. 51(6) (2020) 589\u2013592.","DOI":"10.1016\/j.arcmed.2020.05.020"},{"key":"10.1016\/j.intimp.2022.109183_b0390","doi-asserted-by":"crossref","unstructured":"KA, S. and M. TE, Complement and viral pathogenesis, Virology 411(2) (2011) 362\u2013373.","DOI":"10.1016\/j.virol.2010.12.045"},{"key":"10.1016\/j.intimp.2022.109183_b0395","doi-asserted-by":"crossref","unstructured":"M, N. and R. G, Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?. Kidney Int. 98(5) (2020) 1084-1087.","DOI":"10.1016\/j.kint.2020.06.026"},{"key":"10.1016\/j.intimp.2022.109183_b0400","doi-asserted-by":"crossref","unstructured":"X. Wang, K.K. Sahu, J. Cerny, Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19, 51(3) (2021) 657\u2013662.","DOI":"10.1007\/s11239-020-02297-z"},{"key":"10.1016\/j.intimp.2022.109183_b0405","doi-asserted-by":"crossref","unstructured":"C, M., et al., Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases, Transl. Res. 220 (2020) 1\u201313.","DOI":"10.1016\/j.trsl.2020.04.007"},{"key":"10.1016\/j.intimp.2022.109183_b0410","doi-asserted-by":"crossref","unstructured":"A. Grifoni, et al., Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals, Cell 181(7) (2020) p. 1489-1501.e15.","DOI":"10.1016\/j.cell.2020.05.015"},{"issue":"5","key":"10.1016\/j.intimp.2022.109183_b0415","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2022.109183_b0420","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","article-title":"TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties","volume":"7","author":"Mosmann","year":"1989","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109183_b0425","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.109183_b0430","doi-asserted-by":"crossref","unstructured":"A. Grifoni, et al., Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals, Cell 181(7) (2020) p. 1489-1501. e15.","DOI":"10.1016\/j.cell.2020.05.015"},{"issue":"2","key":"10.1016\/j.intimp.2022.109183_b0435","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0025817220926915","article-title":"Thromboinflammatory response in SARS-CoV-2 sepsis","volume":"88","author":"Maiese","year":"2020","journal-title":"Med. Leg. J."},{"key":"10.1016\/j.intimp.2022.109183_b0440","doi-asserted-by":"crossref","unstructured":"D. Blanco-Melo, et al., Imbalanced host response to SARS-CoV-2 drives development of COVID-19, Cell 181(5) (2020) p. 1036-1045. e9.","DOI":"10.1016\/j.cell.2020.04.026"},{"issue":"1","key":"10.1016\/j.intimp.2022.109183_b0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-021-00258-1","article-title":"Distinct uptake, amplification, and release of SARS-CoV-2 by M1 and M2 alveolar macrophages","volume":"7","author":"Lv","year":"2021","journal-title":"Cell Discovery"},{"key":"10.1016\/j.intimp.2022.109183_b0450","doi-asserted-by":"crossref","unstructured":"M. Gheblawi, et al., Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2, 126 (2020) 1456\u20131474.","DOI":"10.1161\/CIRCRESAHA.120.317015"},{"key":"10.1016\/j.intimp.2022.109183_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102887","article-title":"The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19)","volume":"58","author":"Domingo","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2022.109183_b0460","doi-asserted-by":"crossref","unstructured":"ME, E.S., et al., Activation of B cells by antigens on follicular dendritic cells, Trends Immunol. 31(6) (2010) 205\u2013211.","DOI":"10.1016\/j.it.2010.03.002"},{"issue":"11","key":"10.1016\/j.intimp.2022.109183_b0465","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1007\/s10067-020-05359-y","article-title":"High levels of anti-SSA\/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review: High levels of anti-SSA\/Ro antibodies in COVID-19","volume":"39","author":"Fujii","year":"2020","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109183_b0470","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s11239-020-02182-9","article-title":"Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients","volume":"50","author":"Zhang","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"issue":"6515","key":"10.1016\/j.intimp.2022.109183_b0475","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.intimp.2022.109183_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102683","article-title":"Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19","volume":"122","author":"Rodriguez-Perez","year":"2021","journal-title":"J. Autoimmun."},{"issue":"12","key":"10.1016\/j.intimp.2022.109183_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102695","article-title":"SARS-CoV-2, the autoimmune virus","volume":"19","author":"Halpert","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2022.109183_b0490","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/cts.13026","article-title":"Antinuclear antibodies in COVID 19","volume":"14","author":"Muratori","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.intimp.2022.109183_b0495","doi-asserted-by":"crossref","unstructured":"Y, Z., et al., Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients, Thromb Thrombolysis 50(3) (2020) 580\u2013586.","DOI":"10.1007\/s11239-020-02182-9"},{"key":"10.1016\/j.intimp.2022.109183_b0500","doi-asserted-by":"crossref","unstructured":"Y. Zhang, et al., Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients, 50(3) (2020) 580\u2013586.","DOI":"10.1007\/s11239-020-02182-9"},{"issue":"3","key":"10.1016\/j.intimp.2022.109183_b0505","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc2013656","article-title":"Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19","volume":"383","author":"Bowles","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.109183_b0510","doi-asserted-by":"crossref","first-page":"e001580","DOI":"10.1136\/rmdopen-2021-001580","article-title":"Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review","volume":"7","author":"Taha","year":"2021","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.intimp.2022.109183_b0515","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1111\/cts.13036","article-title":"Autoantibodies in moderate and critical cases of COVID-19","volume":"14","author":"Chang","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.intimp.2022.109183_b0520","doi-asserted-by":"crossref","unstructured":"H, F., et al., High levels of anti-SSA\/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review: high levels of anti-SSA\/Ro antibodies in COVID-19, Clin. Rheumatol. 39(11) (2020) 3171\u20133175.","DOI":"10.1007\/s10067-020-05359-y"},{"issue":"8","key":"10.1016\/j.intimp.2022.109183_b0525","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/jth.14867","article-title":"Lupus anticoagulant is frequent in patients with Covid-19","volume":"18","author":"Harzallah","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.intimp.2022.109183_b0530","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11239-020-02335-w","article-title":"Lupus anticoagulant and mortality in patients hospitalized for COVID-19","volume":"52","author":"Gazzaruso","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.intimp.2022.109183_b0535","unstructured":"Y., X.Z. and Z. S, Brief report: anti-phospholipid antibodies in critically-ill patients with coronavirus disease 2019 COVID-19, Arthritis Rheum. 72(12) (2020) 1998\u20132004."},{"key":"10.1016\/j.intimp.2022.109183_b0540","doi-asserted-by":"crossref","unstructured":"G, V., et al., Autoantibodies related to systemic autoimmune rheumatic diseases in severely-ill patients with COVID-19, Ann. Rheum. Dis. 79(12) (2020) 1661\u20131663.","DOI":"10.1136\/annrheumdis-2020-218009"},{"issue":"3","key":"10.1016\/j.intimp.2022.109183_b0545","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00415-020-10108-x","article-title":"Immune-mediated neurological syndromes in SARS-CoV-2-infected patients","volume":"268","author":"Guilmot","year":"2021","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109183_b0550","first-page":"328","article-title":"Detection of anti-heparin-PF4 complex antibodies in COVID-19 patients on heparin therapy","volume":"18","author":"Dragonetti","year":"2020","journal-title":"Blood Transfus"},{"issue":"7","key":"10.1016\/j.intimp.2022.109183_b0555","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1007\/s10067-021-05580-3","article-title":"Anti-phospholipids antibodies and immune complexes in COVID-19 patients: a putative role in disease course for anti-annexin-V antibodies","volume":"40","author":"Cristiano","year":"2021","journal-title":"Clin. Rheumatol."},{"issue":"102683","key":"10.1016\/j.intimp.2022.109183_b0565","article-title":"Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19","volume":"122","author":"Rodriguez-Perez","year":"2021","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.intimp.2022.109183_b0570","article-title":"COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases","volume":"17","author":"Saad","year":"2021","journal-title":"Bentham Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.109183_b0575","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13256-020-02582-8","article-title":"Systemic lupus erythematosus manifestation following COVID-19: a case report","volume":"15","author":"Zamani","year":"2021","journal-title":"J. Med. Case Rep."},{"issue":"4","key":"10.1016\/j.intimp.2022.109183_b0580","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00296-021-04794-7","article-title":"Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review","volume":"41","author":"Gracia-Ramos","year":"2021","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.intimp.2022.109183_b0585","doi-asserted-by":"crossref","unstructured":"D, W., et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, Jama 323(11) (2020) 1061\u20131069.","DOI":"10.1001\/jama.2020.1585"},{"issue":"1","key":"10.1016\/j.intimp.2022.109183_b0590","first-page":"14","article-title":"Thyrotoxicosis Following SARS-CoV-2 Infection","volume":"7","author":"Harris","year":"2021","journal-title":"AACE Clin. Case Rep."},{"issue":"2","key":"10.1016\/j.intimp.2022.109183_b0595","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/jmv.26513","article-title":"Systemic lupus erythematosus and varicella-like rash following COVID-19 in a previously healthy patient","volume":"93","author":"Slimani","year":"2021","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109183_b0600","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00415-020-10124-x","article-title":"Guillain-Barr\u00e9 syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases","volume":"1268","author":"Abu-Rumeileh","year":"2021","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109183_b0605","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/NRL.0000000000000291","article-title":"Guillain-Barr\u00e9 Syndrome as a Neurological Complication of Novel COVID-19 Infection: A Case Report and Review of the Literature","volume":"25","author":"Paybast","year":"2020","journal-title":"Neurologist."},{"issue":"6","key":"10.1016\/j.intimp.2022.109183_b0615","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/RHU.0000000000001531","article-title":"A case of systemic lupus erythematosus flare triggered by severe coronavirus disease 2019","volume":"26","author":"Raghavan","year":"2020","journal-title":"J. Clin. Rheumatol."},{"issue":"2324709620933438","key":"10.1016\/j.intimp.2022.109183_b0620","article-title":"COVID-19 and Acute Lupus Pneumonitis: Diagnostic and Treatment Dilemma","volume":"8","author":"Kichloo","year":"2020","journal-title":"J. Investig. Med. High Impact Case Rep."},{"issue":"11","key":"10.1016\/j.intimp.2022.109183_b0625","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1177\/0961203320940389","article-title":"Severe refractory thrombocytopenia in a woman positive for coronavirus disease 2019 with lupus and antiphospholipid syndrome","volume":"29","author":"Hayden","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.intimp.2022.109183_b0630","doi-asserted-by":"crossref","unstructured":"S, R., et al., A Case of Systemic Lupus Erythematosus Flare Triggered by Severe Coronavirus Disease 2019, J. Clin. Rheumatol. 26(6) (2020) 234\u2013235.","DOI":"10.1097\/RHU.0000000000001531"},{"key":"10.1016\/j.intimp.2022.109183_b0635","unstructured":"R, B., et al., The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection, Eur. Rev. Med. Pharmacol. Sci. 24(18) (2020) 9695\u20139697."},{"key":"10.1016\/j.intimp.2022.109183_b0640","doi-asserted-by":"crossref","unstructured":"A, H., et al., Severe refractory thrombocytopenia in a woman positive for coronavirus disease 2019 with lupus and antiphospholipid syndrome, Lupus 29(11) (2020) 1472\u20131474.","DOI":"10.1177\/0961203320940389"},{"key":"10.1016\/j.intimp.2022.109183_b0645","doi-asserted-by":"crossref","unstructured":"A, A., et al., COVID-19 in a patient with a flare of systemic lupus erythematosus: A rare case-report, Respir. Med. Case Rep. 31 (2020) p. 101252.","DOI":"10.1016\/j.rmcr.2020.101252"},{"key":"10.1016\/j.intimp.2022.109183_b0650","doi-asserted-by":"crossref","unstructured":"Assini A, B.L., Di Maio S, Schirinzi E, Del Sette M. New, clinical manifestation of COVID\u201019 related Guillain\u2010Barr\u00e8 syndrome highly responsive to intravenous immunoglobulins: two Italian cases, Neurol Sci. 41(7) (2020) 1657\u20131658.","DOI":"10.1007\/s10072-020-04484-5"},{"key":"10.1016\/j.intimp.2022.109183_b0655","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jocn.2020.04.062","article-title":"Guillain Barre syndrome associated with COVID-19 infection: A case report","volume":"76","author":"Sedaghat","year":"2020","journal-title":"J. Clin. Neurosci."},{"issue":"577294","key":"10.1016\/j.intimp.2022.109183_b0660","article-title":"Guillain-Barr\u00e9 syndrome in a patient infected with SARS-CoV-2, a case report","volume":"346","author":"Farzi","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2022.109183_b0665","doi-asserted-by":"crossref","unstructured":"S, A., B. C, and N.W.T. S, Post SARS-CoV-2 Guillain-Barr\u00e9 syndrome, Clin. Neurophysiol. 131(7) (2020) 1652\u20131654.","DOI":"10.1016\/j.clinph.2020.05.003"},{"issue":"6","key":"10.1016\/j.intimp.2022.109183_b0670","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1017\/cjn.2020.106","article-title":"Guillain-Barr\u00e9 Syndrome with Facial Diplegia Related to SARS-CoV-2 Infection","volume":"47","author":"Chan","year":"2020","journal-title":"Can. J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.109183_b0675","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s42466-020-00066-0","article-title":"Guillain-Barr\u00e9 syndrome and SARS-CoV-2","volume":"2","author":"Lampe","year":"2020","journal-title":"Neurol. Res. Pract."},{"issue":"8","key":"10.1016\/j.intimp.2022.109183_b0680","first-page":"513","article-title":"Guillain-Barr\u00e9 Syndrome Associated with SARS-CoV-2 infection","volume":"44","author":"Molina","year":"2020","journal-title":"Med. Intensiva (Engl. Ed)"},{"key":"10.1016\/j.intimp.2022.109183_b0685","doi-asserted-by":"crossref","unstructured":"J. Finsterer, S.F., R. Ghosh, COVID-19 polyradiculitis in 24 patients without SARS-CoV-2 in the cerebro-spinal fluid, J. Med. Virol. 93(1) (2021) p. 66\u201368.","DOI":"10.1002\/jmv.26121"},{"issue":"3","key":"10.1016\/j.intimp.2022.109183_b0690","doi-asserted-by":"crossref","DOI":"10.1093\/tropej\/fmaa044","article-title":"Guillain-Barr\u00e9 Syndrome Associated with SARS-CoV-2 Infection in a Pediatric Patient","volume":"67","author":"Frank","year":"2021","journal-title":"J. Trop. Pediatr."},{"key":"10.1016\/j.intimp.2022.109183_b0695","doi-asserted-by":"crossref","unstructured":"M, M.S., U. E, and C. A, SARS\u2010COV\u20102 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID\u201019, J. Endocrinol. Invest. 43(10) (2020) 1527\u20131528.","DOI":"10.1007\/s40618-020-01366-7"},{"key":"10.1016\/j.intimp.2022.109183_b0700","doi-asserted-by":"crossref","unstructured":"M, C., Z. W, and X. W, Thyroid function analysis in 50 patients with COVID\u201019: a retrospective study, Thyroid 31(1) (2021) p. 8\u201311.","DOI":"10.1089\/thy.2020.0363"},{"issue":"6","key":"10.1016\/j.intimp.2022.109183_b0705","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/bjh.16769","article-title":"Thrombocytopenia as an initial manifestation of COVID-19; case series and literature review","volume":"189","author":"Ahmed","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2022.109183_b0710","doi-asserted-by":"crossref","unstructured":"G, B., M. P, and L. F, COVID\u201019\u2010associated immune thrombocytopenia, Br. J. Haematol. 190(2) (2020) p. e61\u2010e64.","DOI":"10.1111\/bjh.16850"},{"key":"10.1016\/j.intimp.2022.109183_b0715","doi-asserted-by":"crossref","unstructured":"M, M., M. G, and A. E, Clinical characteristics, management and outcome of COVID\u201019\u2010associated immune thrombocytopenia: a French multicentre series. Br. J. Haematol. 190(4) (2020) p. e224\u2010e229.","DOI":"10.1111\/bjh.17024"},{"key":"10.1016\/j.intimp.2022.109183_b0720","doi-asserted-by":"crossref","unstructured":"F.Y. Ayd\u0131n, V. Demircan, Diagnosis and management of coronavirus disease-associated immune thrombocytopenia: a case series, Rev. Soc. Bras. Med. Trop 54 (2021) p. e0029 2021.","DOI":"10.1590\/0037-8682-0029-2021"},{"key":"10.1016\/j.intimp.2022.109183_b0725","unstructured":"A, P., et al., Immune thrombocytopenic purpura\u2014different presentations in two COVID\u201019 patients, Cureus 12(10) (2020) p. e11202."},{"key":"10.1016\/j.intimp.2022.109183_b0730","doi-asserted-by":"crossref","unstructured":"N, G., R. T, S. Yet, SARS\u2010CoV\u20102 Infection Inducing immune thrombocytopenic purpura: case series, Ochsner J. 21(2) (2021) 187\u2013189.","DOI":"10.31486\/toj.20.0100"},{"issue":"6","key":"10.1016\/j.intimp.2022.109183_b0735","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4049\/immunohorizons.1800006","article-title":"IL-22: there is a gap in our knowledge","volume":"2","author":"Zenewicz","year":"2018","journal-title":"Immunohorizons"},{"issue":"9","key":"10.1016\/j.intimp.2022.109183_b0740","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.109183_b0745","article-title":"Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM\u2014a prospective, randomized, single-centre, open-label study","author":"Broman","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"issue":"10230","key":"10.1016\/j.intimp.2022.109183_b0750","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(20)30691-7","article-title":"Immunosuppression for hyperinflammation in COVID-19: a double-edged sword","volume":"395","author":"Ritchie","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2022.109183_b0755","doi-asserted-by":"crossref","first-page":"108655","DOI":"10.1016\/j.intimp.2022.108655","article-title":"COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches","author":"Zavvar","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109183_b0760","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jmii.2020.03.005","article-title":"TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib","volume":"53","author":"Wu","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.intimp.2022.109183_b0765","doi-asserted-by":"crossref","unstructured":"D. Jakhar, I. Kaur, Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus, Nat. Med. 26(5) (2020) 632\u2013632.","DOI":"10.1038\/s41591-020-0853-0"},{"issue":"4102792","key":"10.1016\/j.intimp.2022.109183_b0770","article-title":"The SARS-CoV-2 as an instrumental trigger of autoimmunity","volume":"20","author":"Dotan","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2022.109183_b0775","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/cmi.2017.151","article-title":"Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction","volume":"15","author":"Segal","year":"2018","journal-title":"Cell. Mol. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922006671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922006671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:48:58Z","timestamp":1761587338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922006671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":153,"alternative-id":["S1567576922006671"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109183","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109183"}}